In conclusion, tirabrutinib exerted an anti-tumor effect by regulating multiple BTK downstream signaling proteins, such as NF-κB, AKT, and ERK, in ABC-DLBCL. The gene discussed is MAPK1; the disease is diffuse large B-cell lymphoma.